Vedana emerges with $46m funding to advance next-generation migraine therapies
pharmafile | June 26, 2026 | News story | Research and Development | Vedana Therapeutics, migraine therapies
Vedana Therapeutics has emerged from stealth with $46m in Series A financing to support development of a pipeline of investigational therapies aimed at preventing migraine.
The biotechnology company is developing long-acting antibody therapies targeting pituitary adenylate cyclase-activating polypeptide (PACAP), a biological pathway increasingly being explored as a potential treatment target for migraine.
Migraine affects millions of people worldwide and can have a significant impact on quality of life. Although calcitonin gene-related peptide (CGRP)-targeting medicines have transformed treatment for many patients, the company noted that a substantial proportion continue to experience inadequate symptom control.
Funding from the round will be used to advance Vedana’s portfolio of subcutaneously administered antibodies. Its lead programme targets PACAP, while a second investigational therapy is designed to target both PACAP and CGRP.
Anurag Agarwal, co-founder and CEO of Vedana, said: “First-generation CGRP therapies were a major step forward in the treatment of migraine, but most patients are still not adequately controlled.”
He added that the company was focused on developing treatments targeting biology beyond CGRP, including PACAP, with the aim of improving outcomes for patients.
Vedana’s leadership team includes scientists and clinicians involved in the development of several approved migraine therapies, including anti-CGRP medicines and investigational PACAP-targeting treatments.
Leon Garcia, co-founder and Chief Scientific Officer, said the company had drawn on experience from previous antibody development programmes to create highly potent therapies designed for self-administration at home.
The migraine treatment landscape has expanded significantly in recent years, but unmet need remains high among patients who continue to experience frequent or disabling attacks despite available preventive therapies. Vedana said its programmes are intended to address this gap through novel and combination approaches targeting validated disease pathways.
